International Journal of Technology and Applied Science

E-ISSN: 2230-9004   •   Impact Factor: 9.914

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 17 Issue 11 (November 2026) Submit your research before the last 3 days of this month to publish your research paper in the current issue.

In Silico Drug Repurposing Vs. Anti-Evergreening: Navigating Section 3(d) of the Indian Patents Act in Light of US and Chinese Patent Approaches

Author(s) Ms. Honey Passi, Dr. Pushpanjali Sood
Country India
Abstract In silico drug repurposing involves computational methods such as molecular docking, network pharmacology, machine learning and structure-based prediction to discover new therapeutic uses for already existing drugs. These approaches can speed up drug discovery and lower development costs, but they do have some problems from the point of view of pharmaceutical patentability and how to avoid evergreening. This paper then explores these issues in the light of Section 3(d) of the Patents Act, 1970, by comparing the effectiveness-based exclusion under the Patents Act with the general patentability criteria in the United States and patentability of pharmaceutical-use claims in China. The doctrinal and comparative approach is applied in examining relevant legislation, court rulings, and patent examination documents, to distinguish the practice of therapeutic innovation from an over-ambitious extension of existing patent monopolies by "tinkering" with existing products. It states that computer-discovered items are deserving of neither automatic acceptance of patentability nor automatic exclusion from patentability. Rather, it is the substantive novelty, inventive step, disclosure and evidence which should establish patentability, and not just because of the use of AI. The paper also suggests that while aiming to retain the public health goals of Section 3(d), India should make sure that such goals are applied in the spirit of the patent law, namely on the basis of novel therapeutic uses, including those with respect to a new method of treatment, and not with respect to a new chemical entity. The comparative analysis finally suggests a claim-sensitive approach that strikes a balance between pharmaceutical innovation and access to medicines on the one hand, and patent integrity on the other, while maintaining the purpose of anti-evergreening protection.
Keywords In silico drug repurposing, section 3(d), pharmaceutical patents, evergreening, artificial intelligence, India; United States, China
Field Medical / Pharmacy
Published In Volume 17, Issue 11, November 2026
Published On 2026-11-15

Share this